Janssen’s Linda Wu to head development at Jiangsu Yahong
Plus: new CEO at Atriva, and updates from Hinge Bio, Capsida, Sensorium, CXL and Patient Square
Asieris Pharmaceuticals, also known as Jiangsu Yahong Meditech Co. Ltd. (Shanghai:688176), hired Linda Wu as chief development officer. Wu joins from the Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ), where she was group medical director of oncology, U.S. medical affairs. Asieris is developing treatments for genitourinary tumors and related diseases.
Atriva Therapeutics GmbH named Christian Pangratz CEO, succeeding Rainer Lichtenberger, who co-founded the company. Lichtenberger will work with Pangratz for a transition period of at least six months before retiring this year. Pangratz was CEO at sterna biologicals GmbH & Co. KG. Atriva’s lead product is zapnometinib, a host-targeting agent to inhibit viral replication and modulate the body’s immune response to RNA viruses...